|Articles|October 16, 2020
NeurologyLive Friday 5 — October 16, 2020
Author(s)NeurologyLive® Staff
Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 16, 2020.
Advertisement
Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
1: Early Awareness Towards Epilepsy Transition
Sucheta M. Joshi, MD, MS, FAES, FAAP, and Nicholas Beimer, MD, discussed the reasons why EpiTRAQ may influence earlier discussions with patients prior to the epilepsy transition process.
2: Ana Pereira, MD: Studying Riluzole in Alzheimer Disease
The assistant professor of neurology and neuroscience at Mount Sinai Medical Center discussed the literature that influenced a pilot trial of riluzole in Alzheimer disease.
3: Remote Ischemic Post-Conditioning Shows Significant Benefit With IVT
Investigators noted changes in plasma vascular endothelial growth factor and S100 ß levels indicate a protection-based mechanism derived from the combined treatment.
4: COVID-19 Associated With New Neurologic Disorders, Increased Risk of In-Hospital Mortality
Patients with neurologic disorders were more often older, male, white, hypertensive, diabetic, intubated, and had higher sequential organ failure assessment scores.
5: Peer Exchange: Safety of CGRP Receptor Antagonists vs 5-HT1F Agonists
Peter J. Goadsby, MD, PhD, DSc; Dawn C. Buse, PhD; Jelena Pavlovic, MD, PhD; Wade M. Cooper, DO; and Paul G. Mathew, MD, assess the differences in dosing and adverse-effect profiles when using small-molecule CGRP receptor antagonists rimegepant and ubrogepant vs lasmiditan.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Related Articles
- NeurologyLive® Friday 5 — September 12, 2025
September 12th 2025
- Expanding the Alzheimer Drug Development Pipeline
September 12th 2025
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive
1
MDA and PPMD Release Consensus Guidelines for Safe and Equitable Use of Gene Therapy in Duchenne
2
Expanding the Alzheimer Drug Development Pipeline
3
DORAs Carry Lower Real-World Abuse, New Phase 3 Argus Data, RAP-219 Meets Primary End Point
4
FDA Hands Complete Response Letter to SL1009 for Pyruvate Dehydrogenase Complex Deficiency
5